Funding
The raise is open to qualified institutional and family office investors. Capital is concentrated, milestone-driven and structured for downside protection and risk mitigation — the same discipline and alignment we ask of every founder we back.
Capital supports initial positions in a deliberately focused group of companies working on metabolic fitness, brain health and human performance, alongside reserves for follow-on investment.
Substantial reserves are planned for follow-on investment in companies that demonstrate progress against defined milestones, subject to diligence and the final offering documents.
Capital is set aside for independent, repeatable clinical validation, scientific review, incentive analysis and technical diligence, so claims are tested before they are underwritten.
Fund operations, audit, independent administration and investor reporting are funded as core infrastructure, not as an afterthought.
For investors
For founders
We lead or co-lead early positions where the underlying biology is credible, the science is repeatable and the team can execute against a defined milestone.
Capital is structured to fund the next hard evidence point — a study readout, a device validation, a regulatory step — not an open-ended runway.
Companies that clear their milestone gain access to reserves, downstream co-investors and operating support across science, regulatory and commercial.
Next step
Economics, allocation policy and lifecycle detail are shared with qualified investors under the final offering documents. All terms are indicative until then.